GENB (Generate Biomedicines) FCF Margin %: -640.06% (As of Dec. 2025)


GENB Generate Biomedicines Inc GENB
6 GF Score
Price $16.92
! 2 Warning Signs
View Full Analysis

What is Generate Biomedicines FCF Margin %?

Generate Biomedicines GENB +2.18% 6 FCF Margin % is -640.06% as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 957 Biotechnology companies, Generate Biomedicines ranks worse than 75.03% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Generate Biomedicines's Free Cash Flow for the six months ended in Dec. 2025 was $-204.13 Mil. Generate Biomedicines's Revenue for the six months ended in Dec. 2025 was $31.89 Mil. Therefore, Generate Biomedicines's FCF Margin % for the quarter that ended in Dec. 2025 was -640.06%.

As of today, Generate Biomedicines's current FCF Yield % is -9.42%.

The historical rank and industry rank for Generate Biomedicines's FCF Margin % or its related term are showing as below:

GENB' s FCF Margin % Range Over the Past 10 Years
Min: -640.06   Med: -616.23   Max: -592.39
Current: -640.06

During the past 2 years, the highest FCF Margin % of Generate Biomedicines was -592.39%. The lowest was -640.06%. And the median was -616.23%.

GENB's FCF Margin % is ranked worse than
75.03% of 957 companies
in the Biotechnology industry
Industry Median: -84.65 vs GENB: -640.06

Generate Biomedicines FCF Margin % Related Terms

Generate Biomedicines FCF Margin % Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines FCF Margin % Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
FCF Margin %
-592.39 -640.06

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
FCF Margin % -592.39 -640.06

GENB vs PVLA, SLBT, NKTR: FCF Margin % Comparison

For the Biotechnology subindustry, Generate Biomedicines's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Generate Biomedicines FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generate Biomedicines's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Generate Biomedicines's FCF Margin % falls into.


GENB
6GF Score
Generate Biomedicines Inc GENB
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Generate Biomedicines's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-204.133/31.893
=-640.06 %

Generate Biomedicines's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-204.133/31.893
=-640.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -640.06% mean?
Generate Biomedicines (GENB) has a FCF Margin % of -640.06% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Generate Biomedicines and its competitors. According to the industry distribution chart, Generate Biomedicines ranks #718 out of 957 companies in the Biotechnology industry, placing it in the top 75%.
Is Generate Biomedicines' FCF Margin % too high?
Generate Biomedicines' current FCF Margin % is -640.06%. Based on the distribution chart, Generate Biomedicines ranks #718 out of 957 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' FCF Margin % compare to PVLA and SLBT?
According to the Biotechnology industry distribution chart, Generate Biomedicines ranks #718 out of 957 companies for FCF Margin %. This places Generate Biomedicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current FCF Margin % is -640.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current FCF Margin % of -640.06%. The current FCF Margin % is -640.06%. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current FCF Margin % is -640.06% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.92
Price